Nicholas A. Saccomano's most recent trade in OnKure Therapeutics Inc. - Ordinary Shares - Class A was a trade of 87 Class A Common Stock done at an average price of $3.0 . Disclosure was reported to the exchange on Dec. 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.97 per share. | 22 Dec 2025 | 87 | 7,419 | - | 3.0 | 258 | Class A Common Stock |
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.62 per share. | 22 Sep 2025 | 88 | 3,506 | - | 2.6 | 231 | Class A Common Stock |
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.39 per share. | 23 Jun 2025 | 88 | 3,594 | - | 2.4 | 210 | Class A Common Stock |
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.67 per share. | 04 Apr 2025 | 516 | 3,682 | - | 2.7 | 1,378 | Class A Common Stock |
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.33 per share. | 04 Apr 2025 | 358 | 4,198 | - | 3.3 | 1,191 | Class A Common Stock |
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 130,000 | 130,000 | - | - | Employee Stock Option (right to buy) | |
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 542,232 | 542,232 | - | - | Employee Stock Option (right to buy) | |
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 16,898 | 16,898 | - | - | Employee Stock Option (right to buy) | |
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 8,449 | 8,449 | - | - | Employee Stock Option (right to buy) | |
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 4,556 | 4,556 | - | - | Class A Common Stock | |
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 2,359 | 2,359 | - | - | Employee Stock Option (right to buy) | |
| OnKure Therapeutics Inc (Class A) | Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 1,485 | 1,485 | - | - | Employee Stock Option (right to buy) |